Concord Drugs share price
BSE: 538965Pharmaceuticals & BiotechnologySmall Cap
Share price at the BSE close on 23 Oct 2026. Previous close ₹69.00.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹90 Cr3,001st largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 10 Aug 2026
- 43.7
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 10 Aug 2026
- 5.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 10 Aug 2026
- 7.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 27 May 2026
- 0.28
- Volume, BSEVolume. Shares traded on the last trading day.
- 1,703
Results
Standalone, as consolidated accounts are on record for only 4 of the last ten years; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Jun 2026, against the quarter beforeFiled 10 Aug
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹21 Crdown 41.25%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹1.11 Crup 115.27%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- 5.3%
Revenue by year
Net profit by year, a loss in red
The years either side of a change of basis do not compare. From the year to Mar 2025, the company's revenue for that year, ₹37 Cr, differs from its quarters added, ₹30 Cr.
| ₹ crore | Sep 2024Filed 13 Nov | Dec 2024Filed 12 Jan | Mar 2025Filed 12 Jun | Jun 2025Filed 8 Aug | Sep 2025Filed 14 Feb | Dec 2025Filed 14 Feb | Mar 2026Filed 27 May | Jun 2026Filed 10 Aug |
|---|---|---|---|---|---|---|---|---|
| Revenue | 11.8 | 10.8 | 0.8 | 13.4 | 10.1 | 16.8 | 35.6 | 20.9 |
| Net profit | 0.1 | 0.2 | −7.2 | 0.1 | 0.2 | 0.2 | 0.5 | 1.1 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 0.5% | 2.1% | −902.0% | 0.8% | 1.9% | 1.3% | 1.5% | 5.3% |
The quarters either side of a change of basis do not compare. From the quarter to Mar 2025, the company's revenue for the year to Mar 2025, ₹37 Cr, differs from its quarters added, ₹30 Cr.
Business segments
In the year to Mar 2026 the company reports one business segment, Manufacture of Pharmaceuticals, which carries all its revenue.
Valuation
Today, against the company's own history. Not shown, P/B: the share count changed after the latest balance sheet (a rights issue, a buyback, an allotment or a listing), which does not yet hold the money it brought or returned. Not shown, EV/EBITDA: the share count changed after the latest balance sheet (a rights issue, a buyback, an allotment or a listing), which does not yet hold the money it brought or returned. Dividend yield is not shown: no dividend in the years on record. Its history crosses a change of basis in the accounts in the year to Mar 2025: days before it are of the company before the change.PE ratio and valuation history
At or below today's level on 55% of 1,074 trading days over the last 5 years.
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | +126.0% | +250.8% | −35.6% | 0.0% |
| 3 years | +36.8% | +2.7% | +33.2% | 0.0% |
| 5 years | +19.3% | −22.7% | +54.3% | 0.0% |
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Concord Drugs in market cap. 2 companies in the table last traded before then: their rows are priced on their last trade.
Where the company sits among the companies nearest its size
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 Sotac PharmaceuticalsSOTAC | 102 | 17.6 | 1.7 | – | +0.1% | −28.2% | 10.3% | – | 0.22% |
 Veerhealth CareVEERHEALTH | 99 | 64.4 | 4.3 | 23.3 | +177.2% | +199.7% | 6.8% | 11.0% | 0.00% |
 Parmax PharmaPARMAX | 94 | – | – | – | −17.6% | – | – | −70.0% | 0.00% |
 Amwill Health CareAMWILL | 90 | 7.9 | 1.1 | – | +12.1% | +6.4% | 15.2% | – | 1.11% |
 Vaishali PharmaVAISHALI | 90 | 20.2 | 1.3 | 25.2 | – | – | 6.6% | 4.2% | 0.00% |
 Mercury LaboratoriesMERCURYLAB | 88 | 21.1 | 1.5 | 11.3 | −3.7% | +10.4% | 7.5% | 7.0% | 0.48% |
 Samrat PharmachemSAMRATPH | 86 | – | 1.3 | – | +4.7% | −145.8% | −3.2% | −2.7% | 0.00% |
 Denis Chem LabDENISCHEM | 83 | 10.4 | 0.9 | 3.5 | +4.1% | −5.8% | 9.0% | 10.4% | 4.17% |
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
Sep 2026
30 Sep · Meeting
7 Sep · Letter To Shareholders
7 Sep · Meeting
Concord Drugs share price by year
Each calendar year to 2025.Concord Drugs share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 82.48 | +118.8% | 88.15 | 27.46 |
| 2024 | 37.70 | −36.9% | 56.11 | 32.47 |
| 2023 | 59.72 | +83.5% | 59.72 | 26.15 |
| 2022 | 32.55 | +1.2% | 38.25 | 21.25 |
| 2021 | 32.15 | +40.4% | 42.85 | 21.75 |
| 2020 | 22.90 | +52.7% | 31.25 | 12.29 |
| 2019 | 15.00 | −33.6% | 24.05 | 13.00 |
| 2018 | 22.60 | −29.4% | 32.55 | 17.00 |
| 2017 | 32.00 | −34.7% | 69.45 | 27.10 |
| 2016 | 49.00 | −17.7% | 72.00 | 42.25 |
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on BSE.
| Date | Open | High | Low | Close | Average price | Volume |
|---|---|---|---|---|---|---|
| 23 Oct 2026 | 67.62 | 70.00 | 65.00 | 68.06 | 67.51 | 1,703 |
| 22 Oct 2026 | 68.00 | 69.00 | 65.00 | 69.00 | 67.41 | 1,127 |
| 21 Oct 2026 | 72.78 | 72.78 | 66.50 | 66.77 | 66.95 | 3,322 |
| 19 Oct 2026 | 68.40 | 69.00 | 66.50 | 68.00 | 68.15 | 2,775 |
| 16 Oct 2026 | 73.97 | 73.97 | 66.30 | 68.40 | 70.65 | 4,885 |
| 15 Oct 2026 | 70.10 | 72.40 | 69.50 | 71.69 | 71.36 | 782 |
| 14 Oct 2026 | 73.99 | 73.99 | 70.50 | 70.51 | 71.33 | 3,299 |
| 13 Oct 2026 | 70.50 | 72.50 | 70.10 | 71.40 | 71.54 | 2,288 |
| 12 Oct 2026 | 70.75 | 72.80 | 70.50 | 71.75 | 71.12 | 464 |
| 9 Oct 2026 | 74.00 | 74.00 | 70.05 | 70.40 | 71.45 | 1,862 |
Company details
- Legal name
- Concord Drugs Limited
- BSE code
- 538965
- ISIN
- INE858L01010
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Feb 2015
- Face value
- ₹10
- CIN
- L24230TG1995PLC020093
- Corporate identity number, the registrar of companies' code for it